Results 11 to 20 of about 14,212 (288)
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia [PDF]
Cochrane Database of Systematic Reviews, 2003 Cervical dystonia is the most common form of focal dystonia. It is characterized by involuntary posturing of the head and frequently is associated with neck pain. Disability and social withdrawal are common. Most cases are idiopathic, and generally it is a life-long disorder.
J, Costa +6 more
openaire +6 more sources
Archives of Rehabilitation Research and Clinical Translation, 2021 Objectives: The objectives of this study were to evaluate whether botulinum toxin type A (BoNT-A) treatment for lower limb spasticity leads to patient goal attainment and identify factors associated with positive goal attainment and to assess the effect ...
Subbuh Choudhry, MBBS +4 more
doaj +1 more source
Botulinum toxin type A therapy for blepharospasm [PDF]
Cochrane Database of Systematic Reviews, 2020 This is an update of a Cochrane Review first published in 2005. Blepharospasm is the second most common form of focal dystonia. It is a disabling disorder, characterised by chronic, intermittent or persistent, involuntary eyelid closure, due to spasmodic contractions of the orbicularis oculi muscles.
Duarte, GS +7 more
openaire +5 more sources
Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review
Toxins, 2021 Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis.
Emanuela Martina +4 more
doaj +1 more source
Toxins, 2021 Several studies have investigated the effect of botulinum toxin A (BoNT-A) for managing chronic musculoskeletal pain, bringing contrasting results to the forefront.
Simone Battista +7 more
doaj +1 more source
Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy [PDF]
Anais Brasileiros de Dermatologia, 2014 BACKGROUND: Masseter hypertrophy has been treated with botulinum toxin injections because of esthetic complaints especially in Asians. OBJECTIVES: The goal of the present study was to evaluate the efficacy of abobotulin toxin use in masseter hipertrophy ...
Fernanda Homem de Mello de Souza Klein +4 more
doaj +2 more sources
ABCS Health Sciences, 2022 Introduction: The use of botulinum toxin type A (BTX-A) to correct gummy smile has become popular in recent years. Objective: To evaluate the effects of BTX-A application in the correction of gummy smile 2 and 32 weeks after application.
Carlos Eduardo Alonso Vieira +7 more
doaj +1 more source
Botulinum Toxin Type A for Treatment of Masseter Hypertrophy: Volumetric Analysis of Masseter Muscle Reduction over Time [PDF]
Archives of Aesthetic Plastic Surgery, 2016 Background There has been increasing interest in facial contouring procedures throughout Asian countries. As such, botulinum toxin A injections for masseteric hypertrophy have become a common procedure provided to patients who desire non-surgical ...
Edward Ilho Lee +4 more
doaj +1 more source
Toxins, 2021 Botulinum toxin type A (BoNT-A) represents a first-line treatment for spasticity, a common disabling consequence of many neurological diseases. Electrical stimulation of motor nerve endings has been reported to boost the effect of BoNT-A. To date, a wide
Alessandro Picelli +6 more
doaj +1 more source
Treating the face of women with botulinum toxin type A: 7-year review [PDF]
Revista Brasileira de Cirurgia Plástica, 2023 Introduction: Botulinum toxin type A (BTX-A) is the number one aesthetic procedure worldwide, and the difficulty in standardizing the aesthetic treatment of the face results in a broad range of treatment possibilities.
Victor Hugo Lara Cardoso Sá +3 more
doaj +1 more source